Pacira BioSciences (NASDAQ:PCRX) vs. I-Mab (NASDAQ:IMAB) Head to Head Contrast

Pacira BioSciences (NASDAQ:PCRX) and I-Mab (NASDAQ:IMAB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations and earnings.

Insider & Institutional Ownership

99.7% of Pacira BioSciences shares are owned by institutional investors. Comparatively, 38.4% of I-Mab shares are owned by institutional investors. 6.4% of Pacira BioSciences shares are owned by insiders. Comparatively, 22.1% of I-Mab shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Pacira BioSciences and I-Mab’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pacira BioSciences	-13.07%	13.42%	7.19%
I-Mab	N/A	N/A	N/A

Valuation & Earnings

This table compares Pacira BioSciences and I-Mab”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacira BioSciences	$702.77 million	1.60	$41.96 million	($2.28)	-10.63
I-Mab	$3.27 million	62.13	-$206.44 million	N/A	N/A

Pacira BioSciences has higher revenue and earnings than I-Mab.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Pacira BioSciences and I-Mab, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacira BioSciences	1	4	4	0	2.33
I-Mab	0	0	2	1	3.33

Pacira BioSciences presently has a consensus target price of $26.44, indicating a potential upside of 9.09%. I-Mab has a consensus target price of $5.50, indicating a potential upside of 120.88%. Given I-Mab’s stronger consensus rating and higher probable upside, analysts clearly believe I-Mab is more favorable than Pacira BioSciences.

Volatility & Risk

Pacira BioSciences has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500. Comparatively, I-Mab has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500.

Summary

I-Mab beats Pacira BioSciences on 7 of the 13 factors compared between the two stocks.

About Pacira BioSciences

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

About I-Mab

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.